Corvus Pharmaceuticals (CRVS) News Today

Vanguard Group Inc. lifted its holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 10.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,493,357 shares of the company's stock after purchasing an

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) was the recipient of a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 1,150,000 shares, a decrease of 8.0% from the July 15th total of 1,250,000 shares. Based on an average trading volume of 246,500 shares, the days-to-cover ratio is presently 4.7 days.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.05. During the same quarter in the prior year, the company posted ($0.14) EPS.

Corvus Pharmaceuticals (NASDAQ:CRVS) Share Price Passes Below 50-Day Moving Average of $2.02

Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Crosses Below 50 Day Moving Average of $1.98

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) was the target of a significant growth in short interest in May. As of May 31st, there was short interest totalling 1,520,000 shares, a growth of 17.8% from the May 15th total of 1,290,000 shares. Based on an average daily trading volume, of 235,300 shares, the days-to-cover ratio is currently 6.5 days.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) saw a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 1,290,000 shares, a drop of 5.1% from the April 30th total of 1,360,000 shares. Based on an average daily volume of 248,500 shares, the days-to-cover ratio is currently 5.2 days.

Corvus Pharmaceuticals (NASDAQ:CRVS) Share Price Crosses Above 50-Day Moving Average of $1.77

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) insider William Benton Jones acquired 20,000 shares of the stock in a transaction dated Monday, May 6th. The shares were purchased at an average price of $1.73 per share, for a total transaction of $34,600.00. Following the completion of the transaction, the insider now owns 153,773 shares of the company's stock, valued at approximately $266,027.29. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Oppenheimer upped their target price on shares of Corvus Pharmaceuticals from $7.00 to $8.00 and gave the stock an "outperform" rating in a research report on Tuesday.

Corvus Pharmaceuticals (NASDAQ:CRVS) will be releasing earnings after the market closes on Monday, May 6, Zacks reports.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 1,400,000 shares, a decrease of 6.0% from the March 15th total of 1,490,000 shares. Currently, 3.8% of the shares of the stock are sold short. Based on an average trading volume of 212,900 shares, the days-to-cover ratio is currently 6.6 days.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for shares of Corvus Pharmaceuticals in a report issued on Monday, April 1st. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will earn ($0.35) pe

Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Corvus Pharmaceuticals in a research note on Monday.

Mizuho reaffirmed a "neutral" rating and set a $3.50 target price on shares of Corvus Pharmaceuticals in a research report on Wednesday.

Oppenheimer cut their price target on Corvus Pharmaceuticals from $8.00 to $7.00 and set an "outperform" rating for the company in a research note on Wednesday.

Corvus Pharmaceuticals (NASDAQ:CRVS) will be releasing earnings on Tuesday, March 19, Yahoo Finance reports.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) was the target of a large decline in short interest in February. As of February 15th, there was short interest totalling 1,270,000 shares, a decline of 8.0% from the January 31st total of 1,380,000 shares. Approximately 3.4% of the shares of the stock are short sold. Based on an average trading volume of 206,300 shares, the short-interest ratio is currently 6.2 days.